Imatinib is a targeted therapy that inhibits specific proteins to stop the growth of malignant cancer cells.
Imatinib belongs to a group of medicines called tyrosine-kinase inhibitors. It works by blocking signals that allow certain abnormal cells to grow and survive. In Hong Kong, imatinib is approved for use in several cancers and is available under the brand name Gleevec as well as generic versions.
The most widely recognised product containing imatinib is Gleevec® (imatinib mesylate). It is supplied as oral tablets in strengths such as 100 mg, 400 mg and 600 mg. Generic imatinib tablets of the same strengths are also authorised by the Hong Kong Department of Health and can be found in pharmacies and hospitals.
These formulations are intended for oral use and are packaged in blister packs or bottles, depending on the manufacturer. All products are listed on the Hong Kong Drug Office’s database of registered medicines.
Imatinib is used to manage several serious medical conditions, most of which involve abnormal cell growth. The main indications include:
These uses are approved by the Hong Kong regulatory authorities. In some cases, doctors may prescribe imatinib for off-label situations where the underlying disease shares a similar molecular target, but such decisions are made on an individual basis.
Imatinib interferes with enzymes called tyrosine kinases that act like on-off switches for cell growth. By disabling these switches, the drug slows down or stops the proliferation of abnormal cells while having limited impact on most normal cells. The effect usually begins within a few days, but the full therapeutic benefit may take several weeks to become clear.
People taking imatinib often notice mild, temporary reactions such as:
These symptoms generally diminish as the body adjusts to the medication. If they persist or cause inconvenience, discuss them with a qualified health professional.
Although uncommon, some reactions require urgent medical attention:
Seek emergency care immediately if any of these signs appear.
Imatinib may not be suitable for everyone. Individuals with the following should exercise extra care:
Patients with heart conditions should also inform their clinician, as imatinib can occasionally affect heart rhythm.
Certain substances can alter how imatinib works or increase the risk of side effects:
For a complete list of potential interactions, refer to the specific product’s information leaflet or speak with a pharmacist.
Store imatinib tablets at room temperature, away from moisture and direct sunlight. Keep them out of reach of children. Treatment length varies: some patients take the medicine for a few months, while others may continue for many years under medical supervision. Always follow the instructions that come with the particular product you have.
For detailed dosing, administration and monitoring, see the individual medication’s patient information booklet.
Tyrosine-kinase inhibitor: A drug that blocks enzymes involved in signaling pathways that promote cell growth.
BCR-ABL protein: An abnormal protein produced by a genetic change in certain leukaemias; it drives uncontrolled cell division.
Gastrointestinal stromal tumour (GIST): A tumour arising from the digestive tract’s connective tissue, often linked to mutations that imatinib can target.
This article provides general educational information about imatinib as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing imatinib may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.
